AVYCAZ (ceftazidime, avibactam) by AbbVie is [ see clinical pharmacology ( ) ]. Approved for the following infections caused by designated susceptible gram-negative microorganisms in adult, used in combination with metronidazole ( ) complicated urinary tract infections (cuti), including pyelonephritis ( ) hospital-acquired bacterial pneumonia and 19 more indications. First approved in 2015.
Drug data last refreshed 21h ago · AI intelligence enriched 3w ago
AVYCAZ is a fixed-dose combination of ceftazidime (a third-generation cephalosporin) and avibactam (a beta-lactamase inhibitor) administered intravenously as a powder for reconstitution. It is indicated for treating complicated urinary tract infections (cUTI), complicated intra-abdominal infections (cIAI), and hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible Gram-negative organisms including Pseudomonas aeruginosa and Enterobacteriaceae. The avibactam component restores ceftazidime activity against beta-lactamase-producing resistant organisms by inhibiting key beta-lactamases. AVYCAZ represents an important option for serious nosocomial infections where resistant Gram-negative pathogens limit therapeutic choices.
[ see Clinical Pharmacology ( ) ].
Worked on AVYCAZ at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Trial to Evaluate the Pharmacokinetics and Safety of AVYCAZ(R) in Combination With Aztreonam
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moAVYCAZ employs field-based roles including hospital account managers, infectious disease specialists (MSLs), and pharmacy relationships managers focused on driving adoption in acute care settings where resistant pathogens drive formulary decisions. Key competencies include understanding antimicrobial stewardship programs, managing relationships with infectious disease physicians and hospital epidemiologists, and articulating beta-lactamase inhibition mechanism relative to competitor agents. Currently zero open positions are linked to this product, suggesting stable staffing levels in a mature product.